λ-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration.
Anticoagulants
/ chemistry
Antineoplastic Agents
/ chemistry
Breast Neoplasms
/ drug therapy
Carrageenan
/ chemistry
Cell Line, Tumor
Cell Movement
/ drug effects
Drug Screening Assays, Antitumor
Enzyme Assays
Female
Glucuronidase
/ antagonists & inhibitors
Heparitin Sulfate
/ metabolism
Humans
Oligosaccharides
/ chemistry
anticoagulant
cell migration
depolymerisation
heparanase
λ-carrageenan
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
27 Feb 2019
27 Feb 2019
Historique:
received:
08
01
2019
revised:
15
02
2019
accepted:
22
02
2019
entrez:
2
3
2019
pubmed:
2
3
2019
medline:
18
6
2019
Statut:
epublish
Résumé
In tumor development, the degradation of heparan sulfate (HS) by heparanase (HPSE) is associated with cell-surface and extracellular matrix remodeling as well as the release of HS-bound signaling molecules, allowing cancer cell migration, invasion and angiogenesis. Because of their structural similarity with HS, sulfated polysaccharides are considered a promising source of molecules to control these activities. In this study, we used a depolymerisation method for producing λ-carrageenan oligosaccharides (λ-CO), with progressive desulfation over time. These were then used to investigate the influence of polymeric chain length and degree of sulfation (DS) on their anti-HPSE activity. The effects of these two features on λ-CO anticoagulant properties were also investigated to eliminate a potential limitation on the use of a candidate λ-CO as a chemotherapeutic agent. HPSE inhibition was mainly related to the DS of λ-CO, however this correlation was not complete. On the other hand, both chain length and DS modulated λ-CO activity for factor Xa and thrombin IIa inhibition, two enzymes that are involved in the coagulation cascade, and different mechanisms of inhibition were observed. A λ-carrageenan oligosaccharide of 5.9 KDa was identified as a suitable anticancer candidate because it displayed one of the lowest anticoagulant properties among the λ-CO produced, while showing a remarkable inhibitory effect on MDA-MB-231 breast cancer cell migration.
Identifiants
pubmed: 30818840
pii: md17030140
doi: 10.3390/md17030140
pmc: PMC6471403
pii:
doi:
Substances chimiques
Anticoagulants
0
Antineoplastic Agents
0
Oligosaccharides
0
Carrageenan
9000-07-1
Heparitin Sulfate
9050-30-0
heparanase
EC 3.2.1.-
Glucuronidase
EC 3.2.1.31
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ligue Contre le Cancer
ID : Comité CD17 Charentes Maritimes et CSIRGO
Organisme : AAP Région Nouvelle Aquitaine
ID : "Nanovect" project
Références
J Biol Chem. 2000 Sep 29;275(39):30009-18
pubmed: 10862617
Int J Biol Macromol. 2001 Jun 12;28(5):395-9
pubmed: 11325427
J Clin Invest. 2001 Aug;108(3):341-7
pubmed: 11489924
Environ Health Perspect. 2001 Oct;109(10):983-94
pubmed: 11675262
Guang Pu Xue Yu Guang Pu Fen Xi. 2003 Jun;23(3):600-2
pubmed: 12953553
J Biol Chem. 2004 May 14;279(20):20824-35
pubmed: 14996843
Pharmacol Res. 2004 Jul;50(1):47-53
pubmed: 15082028
Pharmacol Res. 2005 Feb;51(2):153-7
pubmed: 15629261
J Biol Chem. 2005 Apr 1;280(13):12103-13
pubmed: 15647251
Pharmacol Res. 2006 Feb;53(2):129-34
pubmed: 16310373
Curr Pharm Des. 2007;13(20):2057-73
pubmed: 17627539
J Agric Food Chem. 2007 Aug 22;55(17):6910-7
pubmed: 17661479
Br J Cancer. 2007 Sep 17;97(6):761-8
pubmed: 17726466
Int J Mol Med. 2009 Dec;24(6):801-6
pubmed: 19885621
Thromb Haemost. 2009 Nov;102(5):907-11
pubmed: 19888527
Curr Med Chem. 2010;17(23):2503-29
pubmed: 20491645
PLoS One. 2011;6(6):e21106
pubmed: 21698156
Mol Vis. 2012;18:1649-57
pubmed: 22773903
Exp Ther Med. 2011 Mar;2(2):363-367
pubmed: 22977511
Carbohydr Polym. 2013 Jan 16;91(2):483-91
pubmed: 23121936
J Biol Chem. 2013 Jan 4;288(1):223-33
pubmed: 23161548
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Int J Mol Med. 2013 May;31(5):1234-42
pubmed: 23467544
J Biomed Mater Res A. 2014 May;102(5):1431-8
pubmed: 23765560
Anal Bioanal Chem. 2014 Jan;406(1):249-65
pubmed: 24253408
Carbohydr Polym. 2014 Jan 30;101:776-85
pubmed: 24299838
Curr Cancer Drug Targets. 2014;14(3):286-93
pubmed: 24568197
J Med Chem. 2014 Jun 12;57(11):4511-20
pubmed: 24786387
Thromb Res. 2014 May;133 Suppl 2:S90-4
pubmed: 24862152
Adv Food Nutr Res. 2014;72:113-124
pubmed: 25081080
Methods Mol Biol. 2015;1229:105-18
pubmed: 25325948
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5609-21
pubmed: 25337202
Food Chem. 2015 Jul 1;178:311-8
pubmed: 25704717
BMC Med. 2015 Mar 05;13:45
pubmed: 25857315
Carbohydr Polym. 2015 Jul 10;125:76-84
pubmed: 25857962
Mar Drugs. 2015 May 15;13(5):2967-3028
pubmed: 25988519
Sci Rep. 2015 Jun 22;5:11062
pubmed: 26098663
Adv Drug Deliv Rev. 2016 Feb 1;97:237-49
pubmed: 26555370
Nat Struct Mol Biol. 2015 Dec;22(12):1016-22
pubmed: 26575439
Glycobiology. 2016 Jun;26(6):640-54
pubmed: 26762172
Hum Vaccin Immunother. 2016 Sep;12(9):2253-6
pubmed: 27054564
Future Med Chem. 2016 Apr;8(6):647-80
pubmed: 27057774
Eur J Med Chem. 2016 Oct 4;121:209-220
pubmed: 27240275
Nat Biotechnol. 2016 Jun 9;34(6):625-30
pubmed: 27281424
Glycoconj J. 2017 Jun;34(3):411-420
pubmed: 27744520
Iran J Cancer Prev. 2016 Jun 15;9(4):e3836
pubmed: 27761203
Molecules. 2016 Nov 23;21(11):
pubmed: 27886097
Int J Biol Macromol. 2017 Mar;96:282-301
pubmed: 27914965
Carbohydr Polym. 2017 Jun 15;166:156-165
pubmed: 28385219
Mar Drugs. 2017 May 09;15(5):null
pubmed: 28486399
Clin Cancer Res. 2017 Oct 15;23(20):6267-6278
pubmed: 28710312
Chem Commun (Camb). 2017 Aug 10;53(65):9163-9166
pubmed: 28766595
Cancer Treat Rev. 2018 Apr;65:22-32
pubmed: 29502037
Molecules. 2018 Oct 19;23(10):null
pubmed: 30347648
Int J Cancer. 1987 Oct 15;40(4):511-8
pubmed: 3666989
Cancer Chemother Pharmacol. 1995;36(4):325-34
pubmed: 7628052
N Engl J Med. 1995 May 18;332(20):1330-5
pubmed: 7715641
Biochem J. 1993 Jan 15;289 ( Pt 2):331-4
pubmed: 8424778
J Surg Res. 1999 Jan;81(1):42-7
pubmed: 9889056